[ET Net News Agency, 16 April 2024] HSBC Global Research lowered the target price for
Sino Biopharm (01177) to HKD4.5 from HKD4.6 and maintained the "buy" rating.
The research house said it expects low-teens growth for revenue and adjusted net profit
in 2024e-25e. (rc)